Literature DB >> 22989830

Successful treatment of reactive hypoglycemia secondary to late dumping syndrome using miglitol.

Yukari Fujita1, Daisuke Tamada, Junji Kozawa, Yoko Kobayashi, Shugo Sasaki, Tetsuhiro Kitamura, Tetsuyuki Yasuda, Norikazu Maeda, Michio Otsuki, Kohei Okita, Hiromi Iwahashi, Hideaki Kaneto, Tohru Funahashi, Akihisa Imagawa, Iichiro Shimomura.   

Abstract

We herein describe a 59-year-old woman who had undergone a total gastrectomy for gastric carcinoma and suffered from postprandial hypoglycemia characterized by a loss of consciousness and spasms. She was diagnosed with reactive hypoglycemia and treated with nutrition therapy, but the frequency and severity of the hypoglycemic episodes did not decrease. She was subsequently treated successfully with miglitol, an alpha-glucosidase inhibitor (α-GI) taken twice a day; other α-GIs (acarbose and voglibose) were not effective. In conclusion, the administration of miglitol was effective for preventing reactive hypoglycemia secondary to late dumping syndrome.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22989830     DOI: 10.2169/internalmedicine.51.8171

Source DB:  PubMed          Journal:  Intern Med        ISSN: 0918-2918            Impact factor:   1.271


  3 in total

1.  Incretin Kinetics Before and After Miglitol in Japanese Patients With Late Dumping Syndrome.

Authors:  Mari Amagai; Hirohisa Tsuchiya; Yukari Chiba; Jun Suzuki; Jo Nagakura; Erina Shigematsu; Tadashi Yamakawa; Yasuo Terauchi
Journal:  J Clin Med Res       Date:  2017-09-01

2.  Switching α-glucosidase inhibitors to miglitol reduced glucose fluctuations and circulating cardiovascular disease risk factors in type 2 diabetic Japanese patients.

Authors:  Natsuyo Hariya; Kazuki Mochizuki; Seiya Inoue; Miyoko Saito; Masahiro Fuchigami; Toshinao Goda; Takeshi Osonoi
Journal:  Drugs R D       Date:  2014-09

3.  Herbal Medicine for Dumping Syndrome: A Systematic Review and Meta-Analysis.

Authors:  Seungcheol Hong; Bongki Park; Hyeonseok Noh; Dong-Jun Choi
Journal:  Integr Cancer Ther       Date:  2019 Jan-Dec       Impact factor: 3.279

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.